This inventor holds 1 USPTO granted patent. Top assignee: Johns Hopkins University. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Priscilla Brebi-Mieville: Innovator in Cervical Cancer Detection
Introduction
Priscilla Brebi-Mieville is a notable inventor based in Pitrufquen, Chile. She has made significant contributions to the field of medical diagnostics, particularly in the detection of cervical cancer. Her innovative work focuses on identifying epigenetic biomarkers that can improve the diagnosis and monitoring of premalignant lesions.
Latest Patents
Priscilla holds a patent for her research titled "Hypermethylation biomarkers for detection of cervical cancer." This patent addresses the limitations of traditional Pap smears and HPV infection tests, which do not effectively differentiate between lesions that may progress to invasive carcinoma and those that will not. Her research identified hypermethylated genes, such as GGTLA4 and ZNF516, as potential biomarkers for cervical cancer diagnosis. The study revealed that the methylation frequency of these genes was significantly higher in tumor samples compared to normal samples, indicating their potential utility in molecular screening.
Career Highlights
Priscilla is affiliated with The Johns Hopkins University, where she continues her research in cancer diagnostics. Her work has been instrumental in advancing the understanding of epigenetic changes associated with cervical cancer. The findings from her research have implications for improving patient outcomes through better screening methods.
Collaborations
Priscilla has collaborated with esteemed colleagues, including Rafael Guerrero-Preston and David Sidransky. These collaborations have enriched her research and contributed to the advancement of knowledge in the field of cancer diagnostics.
Conclusion
Priscilla Brebi-Mieville's innovative work in identifying methylation biomarkers for cervical cancer detection represents a significant advancement in medical diagnostics. Her contributions have the potential to enhance screening methods and improve patient care in the fight against cervical cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile